Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$126.17 USD

126.17
312,945

+1.92 (1.55%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Hold On to Stryker (SYK) Stock Now

Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.

    New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

    Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

      Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y

      Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.

        Wright Medical Buys Cartiva to Boost Lower Extremities Unit

        Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

          Here's Why You Should Hold On to DexCom (DXCM) Stock Now

          DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.

            STERIS (STE) Strategic Growth Strong, Competition a Woe

            STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

              Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

              Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                Omnicell Patient Engagement Unit to Aid Medication Adherence

                Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                  Here's Why You Should Invest in Integer (ITGR) Stock Now

                  Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

                    Cerner, Duke Clinical Research Launch Risk Calculator App

                    Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.

                      Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails

                      Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.

                        Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                        Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

                          Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates

                          Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.

                            Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)

                            Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                              Align Technology International Growth Solid, Rivalry Rife

                              Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.

                                Why You Should Add Chemed (CHE) Stock to Your Portfolio Now

                                Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.

                                  Here's Why You Should Invest in Illumina (ILMN) Stock Now

                                  Illumina (ILMN) gains on strategic partnerships and international prospects.

                                    Ecolab's New Aquanomic Enhances Laundry Operations at Hotels

                                    Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.

                                      Cerner (CERN) Strong on EHR Prospects, Competition Intense

                                      Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.

                                        Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

                                        Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

                                          DaVita Healthcare Partners' New Facility Now in Los Angeles

                                          DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.

                                            Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now

                                            Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                                              Masimo (MASI) Scales a 52-Week High: What's Driving It?

                                              Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

                                                Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

                                                Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

                                                  Avanos Medical (AVNS) Jumps: Stock Rises 5.5%

                                                  Avanos Medical (AVNS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.